TG-1501 is a novel anti-PDL1 monoclonal antibody
TG-1501 (cosibelimab) is a fully human monoclonal antibody that attaches to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. Cancer cells elude anti-tumor immunity through multiple mechanisms, including upregulated expression of ligands for inhibitory immune checkpoint receptors. Signals from PD-L1 on tumor cells and in the tumor microenvironment help those tumors avoid immune attack and elimination by preventing activation of tumor specific effector T-cells. Anti-PD-L1 antibodies are designed to block that signal, permitting effector T-cells to attack the cancer. Clinical studies have shown that blockade of the PD-1/PD-L1 pathway by monoclonal antibodies can enhance the immune response and result in anti-tumor activity.
This approach has been very successful for a number of diseases, such as Non-small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma and Hodgkin Disease. Limited research into the use of this type of mechanism has been conducted in B-cell cancers such as Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), which is the focus of our research. We believe this mechanism may have a role in treating CLL and NHL, especially in combination with targeted agents (such as umbralisib and TG-1701) and other immune-therapies (such as ublituximab and TG-1801).
Preclinically, it has been shown that the effects of anti-PD-L1 intervention can be enhanced by utilizing other mechanisms targeting the tumor microenvironment. Combining immunotherapies like anti-PD-L1, that counters the tumor’s immune-evading defense system with other anti-cancer agents such as ublituximab and umbralisib may better engage the body’s own immune system to help fight cancer. Studies evaluating this triple combination are underway.
A Phase 1 trial in the US is enrolling patients evaluating TG-1501 alone and in combination with our other drug candidates in patients with CLL and NHL.
Please click here to view currently available clinical trials for TG-1501.
Please click here to view our Publications Page.